Loading
A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Chinese Academy of Sciences, with a status the registry has not verified recently.
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT00576914 by Chinese Academy of Sciences, with 1108 participants planned, started 2007-06 and due to reach its primary completion in 2012-06. Interventions recorded: recombinant human endostatin. Conditions recorded: Non-small Cell Lung Cancer.
Linked to the drug Recombinant human endostatin because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Recombinant human endostatin, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Recombinant human endostatin, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.